vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and SOUTHERN MISSOURI BANCORP, INC. (SMBC). Click either name above to swap in a different company.

SOUTHERN MISSOURI BANCORP, INC. is the larger business by last-quarter revenue ($49.6M vs $38.3M, roughly 1.3× ImmunityBio, Inc.). SOUTHERN MISSOURI BANCORP, INC. runs the higher net margin — 36.6% vs -161.8%, a 198.4% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 10.3%). SOUTHERN MISSOURI BANCORP, INC. produced more free cash flow last quarter ($20.2M vs $-71.3M).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

IBRX vs SMBC — Head-to-Head

Bigger by revenue
SMBC
SMBC
1.3× larger
SMBC
$49.6M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+396.6% gap
IBRX
407.0%
10.3%
SMBC
Higher net margin
SMBC
SMBC
198.4% more per $
SMBC
36.6%
-161.8%
IBRX
More free cash flow
SMBC
SMBC
$91.4M more FCF
SMBC
$20.2M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
IBRX
IBRX
SMBC
SMBC
Revenue
$38.3M
$49.6M
Net Profit
$-61.9M
$18.1M
Gross Margin
99.0%
Operating Margin
-169.0%
45.7%
Net Margin
-161.8%
36.6%
Revenue YoY
407.0%
10.3%
Net Profit YoY
-4.7%
23.9%
EPS (diluted)
$-0.06
$1.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
SMBC
SMBC
Q4 25
$38.3M
$49.6M
Q3 25
$32.1M
$49.0M
Q2 25
$26.4M
$47.6M
Q1 25
$16.5M
$46.1M
Q4 24
$7.6M
$45.0M
Q3 24
$6.1M
$43.8M
Q2 24
$42.9M
Q1 24
$40.1M
Net Profit
IBRX
IBRX
SMBC
SMBC
Q4 25
$-61.9M
$18.1M
Q3 25
$-67.3M
$15.7M
Q2 25
$-92.6M
$15.8M
Q1 25
$-129.6M
$15.7M
Q4 24
$-59.2M
$14.7M
Q3 24
$-85.7M
$12.5M
Q2 24
$13.5M
Q1 24
$11.3M
Gross Margin
IBRX
IBRX
SMBC
SMBC
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IBRX
IBRX
SMBC
SMBC
Q4 25
-169.0%
45.7%
Q3 25
-173.5%
39.7%
Q2 25
-269.8%
40.2%
Q1 25
-390.1%
43.0%
Q4 24
-919.0%
42.7%
Q3 24
-1314.3%
36.1%
Q2 24
39.6%
Q1 24
35.3%
Net Margin
IBRX
IBRX
SMBC
SMBC
Q4 25
-161.8%
36.6%
Q3 25
-209.8%
31.9%
Q2 25
-350.3%
33.2%
Q1 25
-784.9%
34.0%
Q4 24
-783.4%
32.6%
Q3 24
-1404.0%
28.4%
Q2 24
31.6%
Q1 24
28.2%
EPS (diluted)
IBRX
IBRX
SMBC
SMBC
Q4 25
$-0.06
$1.62
Q3 25
$-0.07
$1.38
Q2 25
$-0.10
$1.39
Q1 25
$-0.15
$1.39
Q4 24
$-0.08
$1.30
Q3 24
$-0.14
$1.10
Q2 24
$1.20
Q1 24
$0.99

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
SMBC
SMBC
Cash + ST InvestmentsLiquidity on hand
$242.8M
$134.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$-500.5M
$567.4M
Total Assets
$501.9M
$5.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
SMBC
SMBC
Q4 25
$242.8M
$134.1M
Q3 25
$257.8M
$124.1M
Q2 25
$153.7M
$192.9M
Q1 25
$61.6M
$226.9M
Q4 24
$149.8M
$145.8M
Q3 24
$130.4M
$75.3M
Q2 24
$60.9M
Q1 24
$168.3M
Stockholders' Equity
IBRX
IBRX
SMBC
SMBC
Q4 25
$-500.5M
$567.4M
Q3 25
$-524.3M
$560.2M
Q2 25
$-570.7M
$544.7M
Q1 25
$-591.4M
$528.8M
Q4 24
$-489.1M
$512.4M
Q3 24
$-745.1M
$505.6M
Q2 24
$488.7M
Q1 24
$479.6M
Total Assets
IBRX
IBRX
SMBC
SMBC
Q4 25
$501.9M
$5.1B
Q3 25
$519.0M
$5.0B
Q2 25
$402.1M
$5.0B
Q1 25
$303.8M
$5.0B
Q4 24
$382.9M
$4.9B
Q3 24
$364.6M
$4.7B
Q2 24
$4.6B
Q1 24
$4.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
SMBC
SMBC
Operating Cash FlowLast quarter
$-70.4M
$21.3M
Free Cash FlowOCF − Capex
$-71.3M
$20.2M
FCF MarginFCF / Revenue
-186.2%
40.6%
Capex IntensityCapex / Revenue
2.4%
2.2%
Cash ConversionOCF / Net Profit
1.17×
TTM Free Cash FlowTrailing 4 quarters
$-308.8M
$133.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
SMBC
SMBC
Q4 25
$-70.4M
$21.3M
Q3 25
$-68.9M
$16.3M
Q2 25
$-79.7M
$81.6M
Q1 25
$-85.9M
$24.1M
Q4 24
$-85.1M
$20.1M
Q3 24
$-98.8M
$10.0M
Q2 24
$70.3M
Q1 24
$23.9M
Free Cash Flow
IBRX
IBRX
SMBC
SMBC
Q4 25
$-71.3M
$20.2M
Q3 25
$-69.6M
$15.4M
Q2 25
$-80.8M
$75.3M
Q1 25
$-87.0M
$22.7M
Q4 24
$-87.3M
$18.2M
Q3 24
$-101.6M
$8.6M
Q2 24
$61.2M
Q1 24
$19.6M
FCF Margin
IBRX
IBRX
SMBC
SMBC
Q4 25
-186.2%
40.6%
Q3 25
-217.2%
31.4%
Q2 25
-305.9%
158.1%
Q1 25
-526.9%
49.3%
Q4 24
-1155.4%
40.3%
Q3 24
-1663.2%
19.5%
Q2 24
142.8%
Q1 24
48.8%
Capex Intensity
IBRX
IBRX
SMBC
SMBC
Q4 25
2.4%
2.2%
Q3 25
2.3%
1.8%
Q2 25
4.1%
13.2%
Q1 25
6.8%
3.0%
Q4 24
28.0%
4.4%
Q3 24
45.7%
3.3%
Q2 24
21.1%
Q1 24
10.8%
Cash Conversion
IBRX
IBRX
SMBC
SMBC
Q4 25
1.17×
Q3 25
1.04×
Q2 25
5.17×
Q1 25
1.54×
Q4 24
1.37×
Q3 24
0.80×
Q2 24
5.19×
Q1 24
2.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons